Arvinas shares ticked up modestly by 2.2% following approval and licensing of VEPPANU but the market’s tepid response suggests investors remain cautious about near-term commercial execution and longer-term pipeline visibility.

• The FDA approved VEPPANU, the first PROTAC degrader approved for ESR1-mutant, ER+/HER2- advanced breast cancer, marking a milestone for Arvinas’ platform.
• Arvinas licensed global commercialization, development, and manufacturing rights for VEPPANU to Rigel Pharmaceuticals, opting to focus internal resources on pipeline innovation.
• Phase 1 data for ARV-102 in Parkinson’s disease demonstrated approximately 50% reductions in cerebrospinal fluid LRRK2 at day 14 sustained through day 28, alongside dose-dependent biomarker improvements with good tolerability.
• The company maintains four ongoing Phase 1 clinical programs and a disciplined capital allocation approach but provided limited detail on near-term milestones or revenue guidance from VEPPANU.
• The modest stock movement implies investor reservations on commercial visibility and execution risks despite scientific validation and platform progress.